64 related articles for article (PubMed ID: 23174190)
41. Supervision of multiple signaling protein kinases by the CK2-Cdc37 couple, a possible novel cancer therapeutic target.
Miyata Y; Nishida E
Ann N Y Acad Sci; 2004 Dec; 1030():150-7. PubMed ID: 15659792
[TBL] [Abstract][Full Text] [Related]
42. Signalling and survival pathways in multiple myeloma.
Bommert K; Bargou RC; Stühmer T
Eur J Cancer; 2006 Jul; 42(11):1574-80. PubMed ID: 16797970
[TBL] [Abstract][Full Text] [Related]
43. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma.
Younes H; Leleu X; Hatjiharissi E; Moreau AS; Hideshima T; Richardson P; Anderson KC; Ghobrial IM
Clin Cancer Res; 2007 Jul; 13(13):3771-5. PubMed ID: 17606706
[TBL] [Abstract][Full Text] [Related]
44. IL-6 activated JAK/STAT3 pathway and sensitivity to Hsp90 inhibitors in multiple myeloma.
Kolosenko I; Grander D; Tamm KP
Curr Med Chem; 2014; 21(26):3042-7. PubMed ID: 24735367
[TBL] [Abstract][Full Text] [Related]
45. Emerging pathways as individualized therapeutic target of multiple myeloma.
Misso G; Zappavigna S; Castellano M; De Rosa G; Di Martino MT; Tagliaferri P; Tassone P; Caraglia M
Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S95-109. PubMed ID: 23738692
[TBL] [Abstract][Full Text] [Related]
46. Therapeutic approaches to myeloma bone disease: an evolving story.
Longo V; Brunetti O; D'Oronzo S; Dammacco F; Silvestris F
Cancer Treat Rev; 2012 Oct; 38(6):787-97. PubMed ID: 22494965
[TBL] [Abstract][Full Text] [Related]
47. [Molecular pathogenesis of myeloma for the therapeutic targets].
Hanamura I
Nihon Rinsho; 2007 Dec; 65(12):2202-8. PubMed ID: 18069261
[TBL] [Abstract][Full Text] [Related]
48. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
49. Innate immunity meets with cellular stress at the IKK complex: regulation of the IKK complex by HSP70 and HSP90.
Salminen A; Paimela T; Suuronen T; Kaarniranta K
Immunol Lett; 2008 Apr; 117(1):9-15. PubMed ID: 18282612
[TBL] [Abstract][Full Text] [Related]
50. Targeting Protein Kinases in Blood Cancer: Focusing on CK1α and CK2.
Spinello Z; Fregnani A; Quotti Tubi L; Trentin L; Piazza F; Manni S
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33918307
[TBL] [Abstract][Full Text] [Related]
51. Kinase inhibitors as potential agents in the treatment of multiple myeloma.
Abramson HN
Oncotarget; 2016 Dec; 7(49):81926-81968. PubMed ID: 27655636
[TBL] [Abstract][Full Text] [Related]
52. New responsibilities for aged kinases in B-lymphomas.
Piazza F; Manni S; Arjomand A; Visentin A; Trentin L; Semenzato G
Hematol Oncol; 2020 Feb; 38(1):3-11. PubMed ID: 31782972
[TBL] [Abstract][Full Text] [Related]
53. A review of Glycogen Synthase Kinase-3 (GSK3) inhibitors for cancers therapies.
Thapa R; Gupta G; Bhat AA; Almalki WH; Alzarea SI; Kazmi I; Saleem S; Khan R; Altwaijry N; Dureja H; Singh SK; Dua K
Int J Biol Macromol; 2023 Dec; 253(Pt 7):127375. PubMed ID: 37839597
[TBL] [Abstract][Full Text] [Related]
54. The Role of Endoplasmic Reticulum Stress-Glycogen Synthase Kinase-3 Signaling in Atherogenesis.
Huang A; Patel S; McAlpine CS; Werstuck GH
Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29848965
[TBL] [Abstract][Full Text] [Related]
55. Regulation of taurine transport systems by protein kinase CK2 in mammalian cells.
Lambert IH; Hansen DB
Cell Physiol Biochem; 2011; 28(6):1099-110. PubMed ID: 22178999
[TBL] [Abstract][Full Text] [Related]
56. Joining the cell survival squad: an emerging role for protein kinase CK2.
Ahmed K; Gerber DA; Cochet C
Trends Cell Biol; 2002 May; 12(5):226-30. PubMed ID: 12062170
[TBL] [Abstract][Full Text] [Related]
57. Pathophysiology and pharmacological targeting of tumor-induced bone disease: current status and emerging therapeutic interventions.
Labropoulou VT; Theocharis AD; Symeonidis A; Skandalis SS; Karamanos NK; Kalofonos HP
Curr Med Chem; 2011; 18(11):1584-98. PubMed ID: 21428887
[TBL] [Abstract][Full Text] [Related]
58. Targeting NF-κB Signaling for Multiple Myeloma.
Wong AH; Shin EM; Tergaonkar V; Chng WJ
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32781681
[TBL] [Abstract][Full Text] [Related]
59. The cellular biology of plasma cells: Unmet challenges and opportunities.
Bonaud A; Khamyath M; Espéli M
Immunol Lett; 2023 Feb; 254():6-12. PubMed ID: 36646289
[TBL] [Abstract][Full Text] [Related]
60. Novel players in multiple myeloma pathogenesis: role of protein kinases CK2 and GSK3.
Piazza F; Manni S; Semenzato G
Leuk Res; 2013 Feb; 37(2):221-7. PubMed ID: 23174190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
